Last reviewed · How we verify
Baminercept alfa 3
Baminercept alfa 3 is a fusion protein that targets and modulates the activity of TGF-beta superfamily members.
Baminercept alfa 3 is a fusion protein that targets and modulates the activity of TGF-beta superfamily members. Used for Idiopathic pulmonary fibrosis.
At a glance
| Generic name | Baminercept alfa 3 |
|---|---|
| Also known as | BG9924, LT beta |
| Sponsor | Biogen |
| Drug class | Fibrogenic cytokine inhibitor |
| Target | TGF-beta superfamily members |
| Modality | Biologic |
| Therapeutic area | Fibrosis, Oncology |
| Phase | Phase 2 |
Mechanism of action
Baminercept alfa 3 works by binding to and inhibiting the activity of TGF-beta superfamily members, which play a key role in the pathogenesis of various diseases. This inhibition can lead to a reduction in inflammation and fibrosis, and may have therapeutic benefits in conditions such as fibrosis and cancer. However, the exact mechanism of action of baminercept alfa 3 is complex and not fully understood.
Approved indications
- Idiopathic pulmonary fibrosis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- 104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants (PHASE2)
- Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baminercept alfa 3 CI brief — competitive landscape report
- Baminercept alfa 3 updates RSS · CI watch RSS
- Biogen portfolio CI